Hearzap is a hearing care and audiology startup based in Hyderabad, India, that runs hearing clinics and sells hearing aids for people with hearing loss.

This Startup Deep Dive explains what Hearzap does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Hearzap in Brief

• What it is: Hearzap is an Indian Hearing care clinic chain company based in Hyderabad.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Hearzap operates a network of hearing care centres offering hearing tests, hearing aids, audiology and speech and hearing rehabilitation.
• After the Amplifon India deal it reports about 420 centres and more than 1,000 service providers.
• It uses digital applications for remote diagnostics and virtual shopping for hearing care.
• Funding: About $6 million (reported; sources differ, one profile lists $7.17 million).

Hearzap Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Hearzap?

Hearzap operates in the Hearing care clinic chain space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Hearzap.

• Hearzap operates a network of hearing care centres offering hearing tests, hearing aids, audiology and speech and hearing rehabilitation.
• After the Amplifon India deal it reports about 420 centres and more than 1,000 service providers.
• It uses digital applications for remote diagnostics and virtual shopping for hearing care.
• It launched Zenaud, described as India's first rechargeable in-the-canal hearing aid, developed with GN Hearing and sold through Hearzap (reported).

The Origin Story of Hearzap

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Selvaraj Rajapandian (known as S. Raja).
• S. Raja is an audiologist and the founder and managing director; he says his father, Mr. Selvaraj, began personalised hearing care services in 1977.
• The business began as New Modern Ear Aids, a hearing aid dispensary, then became Hearing Solutions (the legal entity, Hearing Solutions Pvt Ltd) and later the Hearzap brand, billed as India's first digital hearing care ecosystem.
• Raja describes the idea as blending that family legacy with digital tools.
• Reports differ on the founding year (2018 vs 2021) and one profile lists Anurag Kumar as a co-founder.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Hearing care clinic chain sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• November 2023: raised a Rs 50 crore Series A from 360 ONE's healthcare fund; the chain then had more than 90 clinics in seven states and 100+ audiologists.
• April 2024: opened its 100th store, in Jubilee Hills, Hyderabad (reported).
• September 2024: acquired a majority stake (reported as 51%) in Speech and Hearing Care, a Bihar and Jharkhand player, from internal cash flows.
• January 2026: launched Zenaud rechargeable ITC hearing aid.
• May 2026: signed a definitive agreement to buy Amplifon India's hearing healthcare business; completed August 2026, adding about 240 points of sale (115 directly operated) for a network of about 420 centres.

Hearzap Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• November 2023: Rs 50 crore (about $6 million) Series A led by 360 ONE Healthcare Opportunities Fund, with Veda Corporate Advisors as financial adviser (reported), for a minority stake; funds for national expansion over three years.
• 360 ONE Asset Management is reported to back the Amplifon India acquisition.
• Total funding listed as about $6.01 million (Inc42) or $7.17 million (CB Insights).

How Does Hearzap Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Revenue comes from hearing tests, hearing aid sales and audiology services at company-operated and partner points of sale.
• Clinics double as retail stores for hearing aids from partner manufacturers.
• Growth comes both from opening centres and from acquisitions.

The Numbers: Hearzap Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY24: revenue about Rs 70.6 crore.
• FY25: revenue about Rs 84.4 crore, up 19.5%, with a net loss of about Rs 15.3 crore and estimated EBITDA of about -Rs 10.5 crore (profile site; the page has internal inconsistencies, so treat as estimates).
• Combined business expected to cross Rs 230 crore in revenue after the Amplifon India integration (company-stated).

Market Opportunity for Hearzap

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Management targets about Rs 250 crore revenue by the end of the current financial year and nearly Rs 500 crore by FY2029 (company-stated).

Technology and Product at Hearzap

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Plans include AI-enabled diagnostics and tele-audiology (company-stated).
• Zenaud is described as a rechargeable in-the-canal hearing aid (company-stated).

Team and Culture at Hearzap

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Selvaraj Rajapandian serves as founder and managing director.

Hearzap Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Hearzap

• Hearzap must integrate Amplifon India's operations over roughly 12 months while keeping clinical services continuous, which is a large step up from its prior size.
• It reported a net loss of about Rs 15 crore on Rs 84 crore revenue in FY25 (profile site).
• The India hearing aid market has multinational manufacturers competing alongside regional distributors.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Hearzap Growth Outlook: What to Watch

• Company-stated aim of 500 centres by 2027.
• Company-stated targets of about Rs 250 crore revenue this financial year and nearly Rs 500 crore by FY2029.
• Plans to open new centres, enter underserved markets and build rehabilitation services and partnerships with institutions and insurers.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Hearzap can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Hearzap Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Hearzap

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Hearzap.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Hearzap

Studying a company in the Hearing care clinic chain space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Hearzap.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Hearzap as a Startup

• Customer clarity: Can Hearzap name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Hearzap is part of India’s growing Hearing care clinic chain ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Hearzap FAQs: Frequently Asked Questions

What is Hearzap?

Hearzap is a hearing care and audiology startup based in Hyderabad, India, that runs hearing clinics and sells hearing aids for people with hearing loss. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Hearzap?

Hearzap was founded by Selvaraj Rajapandian (known as S. Raja), and the company reports a founding year of 2018 (reports differ: 2021 in one profile; family hearing-aid business dates to 1977).

How much funding has Hearzap raised?

About $6 million (reported; sources differ, one profile lists $7.17 million). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Hearzap make money?

Hearzap earns revenue from its Hearing care clinic chain products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Hearzap?

Reported rivals include Amplifon India, WS Audiology, Solar Ear. See the competitor comparison above for how they differ.

What are the main risks for Hearzap?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Saathi Pads — Saathi makes sanitary pads from banana-tree fibre that degrade in months, using a premium-urban/free-rural pricing model | PaySense — PaySense: bought by PayU at a reported $185M valuation in 2020. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.